Bandaríkin - enska - NLM (National Library of Medicine)

macleods pharmaceuticals limited - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1) ]. levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus , streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila , or mycoplasma pneumoniae [see dosage and administration ( 2.1 ) and clinical studies (14.2 )]. mdrsp i

Bandaríkin - enska - NLM (National Library of Medicine)

macleods pharmaceuticals limited - lurasidone hydrochloride (unii: o0p4i5851i) (lurasidone - unii:22ic88528t) - lurasidone hydrochloride is indicated for: • treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see clinical studies (14.1)]. • monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar i disorder (other indication) [see clinical studies (14.2)]. • adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar i disorder (other indication) [see clinical studies (14.2)]. • known hypersensitivity to lurasidone hcl or any components in the formulation. angioedema has been observed with lurasidone [see adverse reactions (6.1)]. • strong cyp3a4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see drug interactions (7.1)]. • strong cyp3a4 inducers (e.g., rifampin, avasimibe, st. john’s wort, phenytoin, carbamazepine, etc.) [see drug interactions (7.1)]. pregnancy exposure registry there is a pregna

Tansanía - enska - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - eszopiclone - oral tablet - 3

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

healol pharmaceuticals sdn. bhd. - aripiprazole -

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bleomycin sulfate 15000 [iu];   - powder for injection - 15000 iu - active: bleomycin sulfate 15000 [iu]   excipient: water for injection - dbl™ bleomycin sulfate for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents; squamous cell carcinoma: head and neck including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingiva, epiglottis, skin, larynx, penis, cervix, and vulva. the response to bleomycin sulfate is poorer in patients with head and neck cancer previously irradiated.

Singapúr - enska - HSA (Health Sciences Authority)

leo pharma asia pte ltd - tinzaparin sodium - injection - 10,000 axa iu/ml - tinzaparin sodium 10,000 axa iu/ml

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms: squamous cell carcinoma of the skin, head and neck, and oesophagus (primary indication). squamous cell carcinoma of the larynx, penis and uterine cervix. squamous cell carcinoma of the bronchus (response infrequent). choriocarcinoma and embryonal cell carcinoma of the testis. advanced hodgkin's disease and other lymphomas. mycosis fungoides note. use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.

Suður-Afríka - enska - South African Health Products Regulatory Authority (SAHPRA)

macleods pharmaceuticals sa (pty) ltd - injection - see ingredients - each vial contains hydrocortisone sodium succinate equivalent to hydrocortisone 100,0 mg

Kenía - enska - Pharmacy and Poisons Board

bleomycin sulfate usp - injection - bleomycin sulfate usp – 15units/vial - bleomycin

Bandaríkin - enska - NLM (National Library of Medicine)

macleods pharmaceuticals limited - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 5 mg - escitalopram tablets is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see clinical studies (14.1)]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram tablets are indicated for the acute treatment of generalized anxiety disorder (gad) in adults [see clinical studies (14.2)]. generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at leas